Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Phase 1

Completed

• Conditions: Systemic Lupus Erythematosis
• Interventions: Drug: Cyclophosphamide; Drug: Hydroxychloroquine; Drug: Hydrocortisone

• Registration Number: NCT02756546
• Lead Sponsor: Cairo University

Brief Summary

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09
• Primary Completion: 2015-09
• Study Completion: 2015-12
• Status Verified: 2016-04
• Study First Submitted: 2016-04-26
• Study First Submitted QC: 2016-04-27
• Last Update Submitted: 2016-04-27
• Study First Posted: 2016-04-29
• Last Update Posted: 2016-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Adult systemic lupus erythematosis patients

Exclusion Criteria

• Patients younger than 18 years, patients with other autoimmune diseases or malignancy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Patients	Hydroxychloroquine	SLE patients further divided into mild and severe patients
Patients	Cyclophosphamide	SLE patients further divided into mild and severe patients
Patients	Hydrocortisone	SLE patients further divided into mild and severe patients

Primary Outcome Measures

Name	Time	Method
MicroRNAs expression level	3 months